written by reader ET-73 ?? (Cancer Teaser, Michael Robinson, Nova-X Report)

by mrproby | August 26, 2016 11:53 am

What is Et-73, and what small biotech company is about to go IPO[1], that controls it?

Endnotes:
  1. IPO: https://www.stockgumshoe.com/tag/ipo/

Source URL: https://www.stockgumshoe.com/2016/08/microblog-et-73/


40 responses to “written by reader ET-73 ?? (Cancer Teaser, Michael Robinson, Nova-X Report)”

  1. We had three different discussions running about this teaser pitch, I’ve collated them all into this one place. It was also discussed quite actively when it was pitched as ET-743 by the same publishers back in February of this year here.

  2. Miceal says:

    PharmaMar (Madrid) some facts:
    Its oncology portfolio has been validated through global partnerships, eg J&J in the US and Taiho in Japan (for Yondelis) and Chugai in certain EU countries (for Aplidin).

    It has a pipeline of cancer drugs with strategic partners, e.g. Yondelis for soft tissue sarcoma in Japan and the US with profit growth from 2017. The 420-patient CORAIL Phase III trial of PM1183 in platinum-resistant ovarian cancer was cleared to continue in August after an interim futility analysis on the first 210 patients. Another pivotal study of PM1183 was initiated in August – the 600-patient Phase III ATLANTIS study will evaluate PM1183 in combination with doxorubicin in patients with small cell lung cancer. The Phase III trial of Aplidin in multiple myeloma reported positive results in March, while a pivotal study of Aplidin in angioimmunoblastic T-cell lymphoma was initiated in June.

    There has been no recent re-affirmation by the company re the US IPO.

  3. Andy says:

    I think this company used to carry the symbool KHL which kind of stood for keyhole limpet or something like that. I want to say Stellar Biotechnologies but before you plunk you money down check it out for yourself. I can’t be that brilliant if I actually bought in.

  4. Egr2know says:

    Though I initially fell for M Robinson’s teaser on Nvidia & then ended my subscription during the trial period, I REALLY resent their TOTAL GREED in their astronomically ridiculous subscription fees! I guess they figure they should be paid by the number of words!!!I also lose patience with their ENDLESS pitches on whatever they pitch about!!!!!

  5. Marec says:

    I found,as tempting as “Money Morning” makes these investments sound ?
    Plus with the usual presentation to indicate you’d better hurry,so to speak,with little else other then high fee’s and you can make a lot of money.
    I patiently investigated, researched and then monitored a few of their recommendations ,determining that I was glad I waited and monitored the understanding and performance of their recommendations.
    Frequently if things sound to good to be true ,more times then not ,they usually are ,and with that it should be enough to say ,most investment considerations merit further research,not allowing for impatience ,or for pie in the sky ,to overcome our hopefully ,wise,well investigated thought out, prudently researched , correctly viewed perception. Lol

  6. Caroline says:

    Ok guys just checked Nasdaq.com for FREE
    There is one biotech coming up called advanced pharma wait until it comes to market ok losse a bit but at least liquid

  7. spirit says:

    Hi, Is there any news about the company behind the Nasdaq listing and ET-73? Is it Janssen Biotech or PharmaMar whose support does not respond unfortunately to my questions. PharmaMar has been listed in Nasdaq since March 2016. Or is it another company? Thank you very much and kind regards from Germany

  8. klingo88 says:

    Hey,
    what ist mit Imagin Medical Aktie ?

  9. Curious says:

    Has anyone heard further info on ET-73? Received another email from Money Morning touting the “IPO”, but I thought that already happened. Also, are they talking about PharmaMar or Janssen…I assumed they were talking about PharmaMar.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.